Clinical trial
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
NCT00379067 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00379067 |
|---|---|
| Title | A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding. |
| Official title | A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma Europe Ltd. Industry Boehringer Ingelheim |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | Tamsulosin OCAS, Placebo |
| Enrollment | 882 |
| Start date | Oct 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 21, 2006 |
| Last update posted | Oct 10, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: